| 期 |
栏目 |
标题 |
文件 |
| 卷 15, 编号 3 (2013) |
Articles |
Gefitinib – terapiya vybora 1-y linii nemelkokletochnogo raka legkogo u bol'nykh s nalichiem mutatsiy v gene EGFR |
|
| 卷 21, 编号 2 (2019) |
Articles |
Unresectable hepatocellular carcinoma: new opportunities and prospects for therapy |
(Rus)
|
| 卷 21, 编号 2 (2019) |
Articles |
The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience |
(Rus)
|
| 卷 21, 编号 1 (2019) |
Articles |
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia |
(Rus)
|
| 卷 22, 编号 4 (2020) |
CLINICAL ONCOLOGY |
Differentiated thyroid cancer |
(Rus)
|
| 卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
(Rus)
(Eng)
|
| 卷 23, 编号 2 (2021) |
CLINICAL ONCOLOGY |
Prostate cancer |
(Rus)
|
| 卷 23, 编号 4 (2021) |
CLINICAL ONCOLOGY |
Gastric cancer: Russian clinical guidelines |
(Rus)
|
| 卷 24, 编号 4 (2022) |
CLINICAL ONCOLOGY |
Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study |
(Rus)
|
| 卷 25, 编号 3 (2023) |
CLINICAL ONCOLOGY |
Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors” |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study |
(Rus)
|
